Overview of Diagnosis and Management of Metastatic Disease to Bone

被引:1
作者
Yu, Hsiang-Hsuan Michael [1 ]
Tsai, Ya-Yu [2 ]
Hoffe, Sarah E. [1 ]
机构
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Radiat Oncol, Tampa, FL 33612 USA
[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Epidemiol & Genet, Tampa, FL 33612 USA
关键词
POSITRON-EMISSION-TOMOGRAPHY; RANDOMIZED-TRIAL; 8; GY; ZOLEDRONIC ACID; CANCER-PATIENTS; BREAST-CANCER; SKELETAL COMPLICATIONS; RADIOTHERAPY TRIALS; MULTIPLE FRACTIONS; DOUBLE-BLIND;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Bone metastases occur frequently in patients with advanced cancer and are a serious complication of cancer. The decision to treat is often individualized, based on each patient's clinical presentation, life expectancy, and quality of life. Methods: We reviewed the current literature pertaining to management of metastatic disease to bone, and the medical, radiotherapeutic, and surgical treatment options for management of bone metastasis are discussed. Results: Current management of skeletal metastasis includes analgesia, systemic therapy, radiation therapy, and surgery. We propose treatment algorithms for management of vertebral and nonvertebral bone metastases and suggest individualized interventions based on clinical presentation. Conclusions: Management of bone metastases is complex and requires a multidisciplinary approach. The goal of treatment is often palliative, and intervention and treatment regimens should be individualized based on the specific clinical presentation of each patient.
引用
收藏
页码:84 / 91
页数:8
相关论文
共 75 条
[1]   Transdermal fentanyl versus sustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life [J].
Ahmedzai, S ;
Brooks, D .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1997, 13 (05) :254-261
[2]  
[Anonymous], CA CANC J CLIN
[3]  
Ashton A, 1999, RADIOTHER ONCOL, V52, P111
[4]  
BLITZER PH, 1985, CANCER-AM CANCER SOC, V55, P1468, DOI 10.1002/1097-0142(19850401)55:7<1468::AID-CNCR2820550708>3.0.CO
[5]  
2-M
[6]   Current use of bisphosphonates in oncology [J].
Body, JJ ;
Bartl, R ;
Burckhardt, P ;
Delmas, PD ;
Diel, IJ ;
Fleisch, H ;
Kanis, JA ;
Kyle, RA ;
Mundy, GR ;
Paterson, AHG ;
Rubens, RD .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (12) :3890-3899
[7]   Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies [J].
Body, JJ ;
Diel, IJ ;
Lichinitzer, M ;
Lazarev, A ;
Pecherstorfer, M ;
Bell, R ;
Tripathy, D ;
Bergstronn, B .
BRITISH JOURNAL OF CANCER, 2004, 90 (06) :1133-1137
[8]   Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: A multicenter clinical trial [J].
Carteni, Giacomo ;
Bordonaro, Roberto ;
Giotta, Francesco ;
Lorusso, Vito ;
Scalone, Simona ;
Vinaccia, Vincenza ;
Rondena, Roberta ;
Amadori, Dino .
ONCOLOGIST, 2006, 11 (07) :841-848
[9]  
Cherny N, 2000, J Oncol Manag, V9, P8
[10]   The management of cancer pain [J].
Cherny, NI .
CA-A CANCER JOURNAL FOR CLINICIANS, 2000, 50 (02) :70-116